Presenters: Nancy K. Young, PhD, Honorable Kyle B. Haskins, Penny Clodfelter, LCSW
Many FDCs are excluding clients who are taking prescribed medication to address a co-occurring mental health diagnosis, chronic or acute pain condition, or substance use disorder. There are a myriad of practice and policy concerns expressed by FDC teams surrounding this issue, thus raising the need for thoughtful guidance, greater awareness, and continuing education regarding medical-assisted treatment (MAT). The convergence of various trends, including the advent of new medications for substance use disorders highlight the need for greater understanding of MAT for FDC programs. This workshop presentation will provide an overview of medication assisted treatment and explore key considerations for a way to open the doors for this population. Practice and policy examples and implications for collaborative practice between CWS, treatment, and the Courts will be presented.
To view the presentation from this workshop, please click here.
We are pleased to share the resources that were either mentioned during the presentation, shared by our presenters, or used in developing the content. We hope you find this information helpful as you consider or seek to better serve MAT clients in your FDC. Please email us firstname.lastname@example.org if we can be of further assistance.
Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment (American Society of Addiction Medicine)
The National Center on Substance Abuse and Child Welfare MAT Webinar Series:
MAT During Pregnancy, Post-Natal, and Beyond – Part 1
MAT During Pregnancy, Post-Natal, and Beyond – Part 2
Reminder: This presentation will be updated and presented again on June 19th as part of our FDC Learning Academy Webinar Series. This is a great opportunity – particularly if you were unable to attend this workshop at NADCP or have a colleague who would benefit from this presentation. Please click here to register today!